Stratos Wealth Partners LTD. acquired a new stake in shares of Hill-Rom Holdings Inc (NYSE:HRC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 7,234 shares of the medical technology company’s stock, valued at approximately $576,000.

Several other large investors also recently added to or reduced their stakes in the stock. Sei Investments Co. increased its stake in Hill-Rom Holdings by 20.5% in the second quarter. Sei Investments Co. now owns 142,070 shares of the medical technology company’s stock valued at $11,309,000 after buying an additional 24,130 shares during the last quarter. Foster & Motley Inc. bought a new stake in Hill-Rom Holdings during the second quarter valued at approximately $488,000. Texas Permanent School Fund increased its stake in Hill-Rom Holdings by 1.5% in the second quarter. Texas Permanent School Fund now owns 43,695 shares of the medical technology company’s stock valued at $3,479,000 after buying an additional 636 shares during the last quarter. World Asset Management Inc increased its stake in Hill-Rom Holdings by 4.3% in the second quarter. World Asset Management Inc now owns 4,448 shares of the medical technology company’s stock valued at $354,000 after buying an additional 182 shares during the last quarter. Finally, Rothschild Asset Management Inc. increased its stake in Hill-Rom Holdings by 13.0% in the second quarter. Rothschild Asset Management Inc. now owns 798,512 shares of the medical technology company’s stock valued at $63,570,000 after buying an additional 91,996 shares during the last quarter. 84.00% of the stock is owned by institutional investors.

Shares of Hill-Rom Holdings Inc (NYSE:HRC) opened at 75.32 on Monday. Hill-Rom Holdings Inc has a one year low of $50.50 and a one year high of $84.65. The firm’s 50-day moving average price is $80.60 and its 200 day moving average price is $72.15. The firm has a market cap of $4.96 billion, a P/E ratio of 43.89 and a beta of 1.22.

Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings results on Friday, July 28th. The medical technology company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.90 by $0.01. Hill-Rom Holdings had a return on equity of 19.99% and a net margin of 4.27%. The business had revenue of $689.10 million during the quarter, compared to the consensus estimate of $695.50 million. During the same quarter in the prior year, the company posted $0.81 earnings per share. Hill-Rom Holdings’s revenue was up 5.1% compared to the same quarter last year. Analysts predict that Hill-Rom Holdings Inc will post $3.83 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 15th will be issued a dividend of $0.18 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.72 annualized dividend and a yield of 0.96%. Hill-Rom Holdings’s dividend payout ratio (DPR) is currently 41.62%.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/07/stratos-wealth-partners-ltd-acquires-new-stake-in-hill-rom-holdings-inc-nysehrc.html.

Several research firms have recently commented on HRC. BidaskClub raised Hill-Rom Holdings from a “sell” rating to a “hold” rating in a report on Sunday. Zacks Investment Research downgraded Hill-Rom Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $84.00 price objective on shares of Hill-Rom Holdings in a report on Sunday, July 30th. Cantor Fitzgerald set a $86.00 price objective on Hill-Rom Holdings and gave the company a “hold” rating in a report on Friday, July 28th. Finally, Needham & Company LLC cut their price objective on Hill-Rom Holdings from $95.00 to $93.00 and set a “buy” rating for the company in a report on Friday, July 28th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $88.17.

In other Hill-Rom Holdings news, SVP Paul Sherwood Johnson sold 2,078 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $72.30, for a total value of $150,239.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andreas G. Frank sold 10,660 shares of the company’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $78.62, for a total value of $838,089.20. Following the completion of the transaction, the senior vice president now owns 28,988 shares of the company’s stock, valued at approximately $2,279,036.56. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

Hill-Rom Holdings Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Institutional Ownership by Quarter for Hill-Rom Holdings (NYSE:HRC)

Receive News & Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.